Relmada Therapeutics, Inc. reported that on July 22, 2025, it received approval from Nasdaq to transfer its listing to the Nasdaq Capital Market after failing to maintain a minimum bid price of $1 per share for 30 consecutive days, and has until January 19, 2026, to regain compliance with this requirement.